SG11201903882VA - Il-2 variants for the treatment of autoimmune diseases - Google Patents

Il-2 variants for the treatment of autoimmune diseases

Info

Publication number
SG11201903882VA
SG11201903882VA SG11201903882VA SG11201903882VA SG11201903882VA SG 11201903882V A SG11201903882V A SG 11201903882VA SG 11201903882V A SG11201903882V A SG 11201903882VA SG 11201903882V A SG11201903882V A SG 11201903882VA SG 11201903882V A SG11201903882V A SG 11201903882VA
Authority
SG
Singapore
Prior art keywords
international
english
pct
november
administering
Prior art date
Application number
SG11201903882VA
Inventor
Jeffrey Greve
Original Assignee
Delinia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Delinia Inc filed Critical Delinia Inc
Publication of SG11201903882VA publication Critical patent/SG11201903882VA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111011101 HIM 0110100111111111111111111111111111111111111111110111111 Organization 0 International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/089420 Al 17 May 2018 (17.05.2018) WIPO I PCT (51) International Patent Classification: C07K 14/55 (2006.01) A61K 38/00 (2006.01) Published: C12N 5/0783 (2010.01) — with international search report (Art 21(3)) — before the expiration of the time limit for amending the (21) International Application Number: claims and to be republished in the event of receipt of PCT/US2017/060534 amendments (Rule 48.2(h)) (22) International Filing Date: — with sequence listing part of description (Rule 5.2(a)) 08 November 2017 (08.11.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/419,118 08 November 2016 (08.11.2016) US (71) Applicant: DELINIA, INC. [US/US]; 5980 Horton Street, Suite 470, Emeryville, CA 94608 (US). (72) Inventor: GREVE, Jeffrey; 1066 Park Hills Road, Berke- ley, CA 94708 (US). (74) Agent: KRIKELIS, Basil S. et al.; McCarter & English, LLP, Renaissance Centre, 405 N. Market Street, 8th Floor, Wilmington, DE 19801 (US). Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (81) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (84) 1-1 © ei iv pp ot (54) Title: IL-2 VARIANTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES ---- (57) : This disclosure provides for a method for treating a condition by administering to a subject in need thereof a therapeu- 0 GC , 1 tically-effective amount of a compound that comprises an IL-2 receptor-binding moiety. The methods described in the present disclo- 0 sure provide enhanced pharmacokinetic profiles. The disclosure also provides methods for treating autoimmune disease comprising N administering a therapeutically-effective amount of a fusion protein comprising an IL-2 variant protein. C
SG11201903882VA 2016-11-08 2017-11-08 Il-2 variants for the treatment of autoimmune diseases SG11201903882VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662419118P 2016-11-08 2016-11-08
PCT/US2017/060534 WO2018089420A1 (en) 2016-11-08 2017-11-08 Il-2 variants for the treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
SG11201903882VA true SG11201903882VA (en) 2019-05-30

Family

ID=62065637

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903882VA SG11201903882VA (en) 2016-11-08 2017-11-08 Il-2 variants for the treatment of autoimmune diseases

Country Status (15)

Country Link
US (2) US11077172B2 (en)
EP (1) EP3538548A4 (en)
JP (2) JP2019532996A (en)
KR (1) KR20190083656A (en)
CN (1) CN110167957A (en)
AU (1) AU2017359172A1 (en)
CA (1) CA3041334A1 (en)
CL (1) CL2019001265A1 (en)
CO (1) CO2019005922A2 (en)
EA (1) EA201991142A1 (en)
EC (1) ECSP19041447A (en)
IL (1) IL266178A (en)
MX (1) MX2019005400A (en)
SG (1) SG11201903882VA (en)
WO (1) WO2018089420A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9133244B2 (en) 2011-01-18 2015-09-15 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
ES2884357T3 (en) 2015-10-09 2021-12-10 Bioniz Llc Modulation of gamma-c cytokine activity
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
JP7165717B2 (en) 2017-03-15 2022-11-04 パンディオン・オペレーションズ・インコーポレイテッド target immune tolerance
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
CN111010866A (en) 2017-05-24 2020-04-14 潘迪恩治疗公司 Targeted immune tolerance
RU2020120145A (en) 2017-11-21 2021-12-22 Дзе Борд Оф Трастиз Оф Дзе Лелэнд Стэнфорд Джуниор Юниверсити PARTIAL AGONISTS OF INTERLEUKIN-2
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
JP2021506291A (en) 2017-12-19 2021-02-22 ゼンコア インコーポレイテッド Modified IL-2 FC fusion protein
SG11202008784RA (en) 2018-03-13 2020-10-29 Tusk Therapeutics Ltd Anti-cd25 for tumour specific cell depletion
SG11202009017WA (en) 2018-03-28 2020-10-29 Bristol Myers Squibb Co Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use
AU2019288496A1 (en) * 2018-06-22 2021-01-14 Cugene Inc. Interleukin-2 variants and methods of uses thereof
WO2020007937A1 (en) * 2018-07-03 2020-01-09 Iltoo Pharma Use of interleukin-2 for treating systemic sclerosis
MX2021001493A (en) 2018-08-06 2021-07-15 Medikine Inc Il-2 receptor binding compounds.
US20220025007A1 (en) * 2018-12-21 2022-01-27 Hanmi Pharm. Co., Ltd. Novel immunosuppressive interleukin 2
CA3137971A1 (en) 2019-05-03 2020-11-12 Bioniz, Llc Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders
TW202110885A (en) 2019-05-20 2021-03-16 美商潘迪恩治療公司 Madcam targeted immunotolerance
KR20220051177A (en) 2019-07-26 2022-04-26 비스테라, 인크. Interleukin-2 agonists and uses thereof
CN110642934B (en) * 2019-09-10 2022-08-23 中国医学科学院北京协和医院 Long-acting interleukin-2 of target regulatory T cell and application thereof in treating autoimmune disease
WO2021092075A1 (en) 2019-11-05 2021-05-14 Medikine Inc. IL-2RβγC BINDING COMPOUNDS
EP4055036A4 (en) 2019-11-05 2024-02-28 Medikine, Inc. Dual il-2r and il-7r binding compounds
US20210188934A1 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
AU2021206449A1 (en) 2020-01-10 2022-07-21 Bright Peak Therapeutics Ag Modified IL-2 polypeptides and uses thereof
IL294070A (en) * 2020-01-14 2022-08-01 Synthekine Inc Il2 muteins
AU2021207652B2 (en) 2020-01-14 2023-08-03 Synthekine, Inc. Biased IL2 muteins methods and compositions
TWI823054B (en) 2020-02-03 2023-11-21 美商麥地金公司 IL-7Rα BINDING COMPOUNDS
TWI812918B (en) 2020-02-03 2023-08-21 美商麥地金公司 IL-7Rαγc BINDING COMPOUNDS
WO2021168079A1 (en) 2020-02-21 2021-08-26 Pandion Operations, Inc. Tissue targeted immunotolerance with a cd39 effector
KR20230112632A (en) 2020-10-23 2023-07-27 애셔 바이오테라퓨틱스, 인크. Fusion with CD8 antigen binding molecules to modulate immune cell function
WO2022094275A1 (en) 2020-10-29 2022-05-05 Bristol-Myers Squibb Company Fusion proteins for the treatment of disease
JP2024502708A (en) 2020-12-04 2024-01-23 ビステラ， インコーポレイテッド Methods of using interleukin-2 agonists
JP2024512418A (en) * 2021-03-31 2024-03-19 ハンミ ファーマシューティカル カンパニー リミテッド Novel immunoactive interleukin 2 analog conjugate and method for producing the same
KR20230095612A (en) * 2021-12-22 2023-06-29 한미약품 주식회사 Novel immune suppressing IL-2 analogs
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
WO2024054868A1 (en) * 2022-09-07 2024-03-14 Xencor, Inc. An il-2 fc fusion protein for use in methods for the treatment of plaque psoriasis and atopic dermatitis
WO2024199458A1 (en) * 2023-03-29 2024-10-03 Wuxi Biologics (Shanghai) Co., Ltd. Il-2 variants with improved stability and compositions thereof

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5466447A (en) 1988-06-29 1995-11-14 Amgen Inc. Method for treating psoriasis
EP0378666A4 (en) 1988-07-05 1992-01-22 Amgen Inc. Interleukin ii analogs
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US6541610B1 (en) * 1989-09-05 2003-04-01 Immunex Corporation Fusion proteins comprising tumor necrosis factor receptor
US5650150A (en) 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
WO1995008340A1 (en) 1993-09-21 1995-03-30 Amgen Inc. Method for treating psoriasis
CN1204147C (en) 1998-02-25 2005-06-01 利思进药品公司 Enhancing circulating half-life of antibody-based fusion proteins
US6955807B1 (en) 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
DZ2788A1 (en) 1998-05-15 2003-12-01 Bayer Ag Selective IL-2 agonists and antagonists.
US6348192B1 (en) 1999-05-11 2002-02-19 Bayer Corporation Interleukin-2 mutein expressed from mammalian cells
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6689353B1 (en) 2000-06-28 2004-02-10 Bayer Pharmaceuticals Corporation Stabilized interleukin 2
ES2322936T3 (en) 2000-09-14 2009-07-02 Beth Israel Deaconess Medical Center, Inc. MODULATION OF THE T-CELL RESPONSES MEDIATED BY IL-2 AND IL-15.
AU2002248571B2 (en) 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2003006501A2 (en) 2001-07-11 2003-01-23 Maxygen Holdings, Ltd. G-csf conjugates
US7314712B2 (en) 2001-07-27 2008-01-01 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Systems for in vivo site-directed mutagenesis using oligonucleotides
US7371371B2 (en) 2001-08-13 2008-05-13 University Of Southern California Interleukin-2 mutants with reduced toxicity
RU2312677C9 (en) 2001-12-04 2008-03-27 Мерк Патент Гмбх Immunocytokines possessing modulated selectivity
JP4629047B2 (en) 2003-06-12 2011-02-09 イーライ リリー アンド カンパニー GLP-1 analog complex protein
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
EP1944318B1 (en) 2003-07-21 2011-03-02 Transgene S.A. Multifunctional cytokines
CA2533512C (en) 2003-07-25 2013-06-11 Amgen Inc. Antagonists and agonists of ldcam and methods of use
RU2006135112A (en) 2004-03-05 2008-04-10 Чирон Корпорейшн (Us) IN VITRO TEST SYSTEM FOR FORECASTING PATIENT RESISTANCE TO THERAPEUTIC MEDICINES
KR20070102576A (en) 2005-01-27 2007-10-18 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 Methods for treating renal cell carcinoma
PT1688146E (en) 2005-02-07 2007-10-29 Novartis Vaccines & Diagnostic Preparing aldesleukin for pharmaceutical use
AU2007271398B2 (en) 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
JP5535633B2 (en) 2006-09-29 2014-07-02 オンコメッド ファーマシューティカルズ インコーポレイテッド Compositions and methods for diagnosis and treatment of cancer
FR2918770B1 (en) 2007-07-10 2009-09-11 Essilor Int DISPLAY TO BE INTEGRATED WITH A PAIR OF EYEWEAR.
US8906356B2 (en) 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
DE102008023820A1 (en) 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg An agent for the treatment and / or prophylaxis of an autoimmune disease and for the production of regulatory T cells
ES2825173T3 (en) 2009-01-21 2021-05-14 Amgen Inc Compositions and methods of treatment of inflammatory and autoimmune diseases
RU2504553C2 (en) 2009-03-20 2014-01-20 Дженентек, Инк. Antibodies to her
EP2542590B2 (en) 2010-03-05 2020-04-01 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
CU23923B1 (en) 2010-11-12 2013-07-31 Ct De Inmunología Molecular POLYPEPTIDES DERIVED FROM IL-2 WITH AGONIST ACTIVITY
PL2637694T3 (en) 2010-11-12 2021-10-18 Nektar Therapeutics Conjugates of an il-2 moiety and a polymer
CN102462837B (en) 2010-11-19 2016-08-03 生物林格斯Ip有限公司 Anti-inflammatory composition
JP6093712B2 (en) 2010-12-22 2017-03-08 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Interleukin 2 superagonist and antagonist
CN102174111B (en) 2011-01-25 2013-01-09 江苏省弗泰生物科技有限公司 Human interleukin-2 (IL-2)/Fc fusion protein and uses
KR101852245B1 (en) * 2011-02-10 2018-04-25 로슈 글리카트 아게 Mutant interleukin-2 polypetides
BR112013023151A2 (en) 2011-03-11 2020-09-15 Assistance Publique - Hôpitaux De Paris interleukin-2 for use in the treatment of autoimmune, immune-related or inflammatory disorder and method for determining whether a regimen or dose of il-2 needs to be modified
EA201892619A1 (en) 2011-04-29 2019-04-30 Роше Гликарт Аг IMMUNOCONJUGATES CONTAINING INTERLEUKIN-2 MUTANT POLYPETIPS
WO2013177187A2 (en) 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
JP2014094898A (en) 2012-11-07 2014-05-22 Univ Of Tsukuba MEDICINE COMPRISING ACTIVE MODULATOR OF CD300a-EXPRESSING CELL ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE, CD300a GENE KNOCK-OUT MOUSE, AND USE OF ACTIVE MODULATOR OF CD300a-EXPRESSING CELL
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
US10544187B2 (en) 2013-03-15 2020-01-28 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
CN103193887B (en) 2013-04-03 2015-02-04 江苏众红生物工程创药研究院有限公司 Recombinant porcine IL2-Fc (interteukin-2-Fc) fusion protein as well as encoding gene and expressing method of fusion protein
US20150017120A1 (en) 2013-06-13 2015-01-15 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy
EA201992609A1 (en) 2014-02-06 2020-03-04 Ф.Хоффманн-Ля Рош Аг FILLED PROTEINS CONTAINING INTERLEUKIN-2 AND THEIR APPLICATIONS
CA2946398A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
AU2015292889C1 (en) 2014-07-21 2023-01-19 Delinia, Inc. Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
AU2015301936B2 (en) 2014-08-11 2019-03-07 Delinia, Inc. Modified IL-2 variants that selectively activate regulatory T cells for the treatment of autoimmune diseases
WO2016025647A1 (en) 2014-08-12 2016-02-18 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
WO2016057651A1 (en) 2014-10-09 2016-04-14 Dana-Farber Cancer Institute, Inc. Multiple-variable il-2 dose regimen for treating immune disorders
US20170204154A1 (en) * 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
JP7422480B2 (en) * 2016-05-04 2024-01-26 アムジエン・インコーポレーテツド Interleukin-2 mutant protein for regulatory T cell proliferation

Also Published As

Publication number Publication date
CL2019001265A1 (en) 2019-10-04
AU2017359172A1 (en) 2019-05-16
MX2019005400A (en) 2019-08-05
EP3538548A4 (en) 2020-08-19
US20180125941A1 (en) 2018-05-10
IL266178A (en) 2019-06-30
EP3538548A1 (en) 2019-09-18
US11077172B2 (en) 2021-08-03
JP2022119829A (en) 2022-08-17
EA201991142A1 (en) 2019-10-31
WO2018089420A1 (en) 2018-05-17
KR20190083656A (en) 2019-07-12
ECSP19041447A (en) 2019-07-31
JP2019532996A (en) 2019-11-14
US20210308222A1 (en) 2021-10-07
CN110167957A (en) 2019-08-23
CA3041334A1 (en) 2018-05-17
CO2019005922A2 (en) 2019-08-30

Similar Documents

Publication Publication Date Title
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201805784PA (en) Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
SG11201909955XA (en) Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201804814YA (en) Materials and methods for delivering nucleic acids to cochlear and vestibular cells
SG11201810600WA (en) Fxr (nr1h4) modulating compounds
SG11201808990QA (en) Compositions for topical application of compounds
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201805422WA (en) Multivalent and multispecific ox40-binding fusion proteins
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201807597UA (en) Methods of treating depression using orexin-2 receptor antagonists
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201809751XA (en) Egfr inhibitor compounds
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201407579QA (en) Interleukin-2 fusion proteins and uses thereof
SG11201908325PA (en) Process for the preparation of glucuronide drug-linkers and intermediates thereof
SG11201900554YA (en) Spiro-lactam nmda modulators and methods of using same
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201903167QA (en) Compounds and methods for reducing atxn3 expression
SG11201901961SA (en) Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
SG11201907364WA (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
SG11201805052YA (en) Therapeutic methods using erythrocytes
SG11201901063SA (en) Therapeutic agents for neurodegenerative diseases